• Number of Treatment Groups - Three sequential dosage groups, one comparative 
group 
• Comparative Group - Non-modified syngeneic lymphocytes 
• Primary Endpoint - Safety 
• Secondary Endpoints - Effects on primary disease status (CD4 count, HIV 
burden, p24 antigen), longevity of genetically modified cells. 
3 . 2 Number of Institutions 
• One institution is expected to participate in this trial. 
3.3 Number of Patients 
• Required Evaluable per dosage cohort in Treatment Period 1-6 
• Total Number of Evaluable Patients - 40 maximum 
3.4 Estimated Study Duration 
• Treatment Duration for Individual Patient - Approximately 1 year 
• Total Study Duration - Approximately 2 years 
4. PATIENT ELIGIBILITY 
Screening tests for eligibility must be completed within 2 weeks of a patient's being registered 
onto the study. If more than 2 weeks elapse between screening and apheresis of the donor, 
HIV positivity tests for the donor must be repeated. 
4. 1 Inclusion Criteria 
4.1.1 An identical twin pair, one of whom is seropositive for HIV, the other twin 
seronegative, by standard ELISA, PCR, and Western blot testing. 
4.1.2 Patients with Kaposi's sarcoma are eligible for this study, but must not 
have received any systemic therapy for KS within 4 weeks prior to entry. 
The diagnosis of KS must have been confirmed by biopsy. 
4.1.3 Anticipated survival > 6 months and Karnofsky Performance Status > 60% 
(Appiendix A). 
4.1.4 18 years of age or older. 
4. 1 .5 Free from serious psychological or emotional illness and able to provide 
written informed consent. 
4.2 Exclusion Criteria - Recipient 
4.2.1 Lymphoma 
4.2.2 Unwillingness to comply with current NIH Clinical Center guidelines 
concerning appropriate notification of all current sexual partners of an 
individual regarding his or her HIV positive sero-status and the risk of 
transmission of HIV infection. 
Recombinant DNA Research, Volume 19 
[139] 
